Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Spero Therapeutics, Inc. Common Stock

SPRO Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of SPRO by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
SPRO Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
SPRO Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SPRO Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in SPRO holdings by institutional investors

Quarterly net insider trading by SPRO's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $20,000 Jul 17, 2022 Issue: Health Issues
  • $50,000 Apr 17, 2022 Issue: Health Issues
  • $50,000 Jan 17, 2022 Issue: Health Issues

Former government officials who have lobbied for SPRO

5 former government officials from 4 congressional offices at 1 lobbying firm have lobbied for SPRO, most recently Dec 15, 2021.

  • Susan W. Brooks
    Kristina Dunklin House New Legislative Director, Rep. Susan Brooks (2018-2019); Legislative Director, Rep. David Valadao (2015-2018); Legislative Assistant, Rep. David Valadao (2014-2015) Formerly with Susan W. Brooks · FORBES-TATE · Dec 15, 2021
  • Mike Crapo
    Barrett Thornhill Senate New Legislative Assistant, Sen. Mike Crapo (2003-2006); Legislative Assistant, Rep. Pat Toomey (2002-2003); Legislative Assistant, Rep. Charlie Norwood (2001-2002) Formerly with Mike Crapo · FORBES-TATE · Dec 15, 2021
  • Paul Dioguardi Congress New Director, Office of Intergovernmental and External Affairs, U.S. Dept. of Health and Human Services (2009-2015); Chief of Staff, Office of Congressional and Intergovernmental Affairs, U.S. Dept. of Labor (1999-2001) Formerly Director, Office of Intergovernmental and External Affairs, U.S. Dept. of Health · FORBES-TATE · Dec 15, 2021
  • Allen Boyd
    Elizabeth Greer House New Chief of Staff, Rep. Allen Boyd (2001-2009) Formerly with Allen Boyd · FORBES-TATE · Dec 15, 2021
  • Orrin G. Hatch
    Derrick White Senate New Deputy Communications Director, Sen. Orrin Hatch (2000-2001) Formerly with Orrin G. Hatch · FORBES-TATE · Dec 15, 2021

SPRO Estimated quarterly lobbying spending

SPRO Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
SPRO Income Statement
SPRO Balance Sheet
SPRO Cash Flow
U.S. Patents

New SPRO patent grants

  • Patent Title: Aryl substituted polymyxin derivatives Jan. 20, 2026
  • Patent Title: Tebipenem pivoxil immediate and modified release oral dosage forms Feb. 18, 2025
  • Patent Title: Polymyxin compounds and uses thereof Nov. 19, 2024
  • Patent Title: Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use Sep. 24, 2024
  • Patent Title: High dosage tebipenem pivoxil tablet formulation Jul. 30, 2024
  • Patent Title: Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use Aug. 08, 2023
  • Patent Title: Polymyxin compounds Oct. 04, 2022
  • Patent Title: Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use Jan. 12, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to SPRO from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
SPRO News

Recent insights relating to SPRO

CNBC Recommendations

Recent picks made for SPRO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SPRO

SPRO Analyst Ratings

SPRO Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
SPRO Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $SPRO stock a Buy, Sell, or Hold?

  • What is the price target for $SPRO stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

SPRO Top Shareholders
Shareholder
Shares Held
SPRO Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $SPRO stock?

  • Who owns the most shares of $SPRO stock?

  • What funds own $SPRO stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

SPRO Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SPRO Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About SPRO

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

  • Address Cambridge, MA
  • Market Cap 73.4 million
  • Employees 25
  • Industrial Classification Pharmaceutical Preparations

Spero Therapeutics, Inc. Common Stock (SPRO) Historical Stock Prices

Spero Therapeutics, Inc. Common Stock (SPRO) closed at $1.26 on September 23, 2026. Over the past year its adjusted close ranged from $1.11 to $2.98. Daily prices go back to January 2, 2014, 2,667 trading days in all.

  • 1 month+3.70%
  • 3 months-40.00%
  • Year to date-45.92%
  • 1 year-37.31%
  • 3 years+4.13%
  • 5 years-93.27%
  • Max-51.35%
See every congressional and insider trade on the SPRO price chart

Quiver Premium charts SPRO's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 1.36 1.40 1.24 1.26 1.26 1,403,213
Sep 22, 2026 1.30 1.44 1.28 1.36 1.36 7,764,493
Sep 21, 2026 1.14 1.15 1.12 1.14 1.14 319,103
Sep 18, 2026 1.12 1.21 1.11 1.13 1.13 501,371
Sep 17, 2026 1.14 1.14 1.11 1.12 1.12 181,774
Sep 16, 2026 1.12 1.14 1.10 1.11 1.11 439,642
Sep 15, 2026 1.14 1.15 1.11 1.13 1.13 225,284
Sep 14, 2026 1.13 1.16 1.13 1.14 1.14 267,141
Sep 11, 2026 1.13 1.15 1.13 1.13 1.13 310,631
Sep 10, 2026 1.18 1.18 1.12 1.12 1.12 569,285
Sep 9, 2026 1.20 1.21 1.17 1.17 1.17 367,060
Sep 8, 2026 1.21 1.22 1.19 1.19 1.19 348,592
Sep 4, 2026 1.20 1.22 1.19 1.21 1.21 362,983
Sep 3, 2026 1.22 1.23 1.20 1.22 1.22 203,326
Sep 2, 2026 1.20 1.24 1.20 1.22 1.22 169,514
Sep 1, 2026 1.22 1.22 1.18 1.20 1.20 385,397
Aug 31, 2026 1.20 1.23 1.20 1.22 1.22 338,465
Aug 28, 2026 1.21 1.22 1.18 1.20 1.20 312,829
Aug 27, 2026 1.22 1.23 1.18 1.21 1.21 538,487
Aug 26, 2026 1.22 1.23 1.20 1.22 1.22 154,762
Aug 25, 2026 1.23 1.26 1.20 1.23 1.23 645,540
Aug 24, 2026 1.22 1.24 1.20 1.22 1.22 367,273
Aug 21, 2026 1.22 1.25 1.21 1.22 1.22 359,140
Aug 20, 2026 1.22 1.27 1.20 1.21 1.21 558,771
Aug 19, 2026 1.20 1.24 1.19 1.23 1.23 480,182
Aug 18, 2026 1.20 1.20 1.18 1.20 1.20 477,408
Aug 17, 2026 1.21 1.24 1.19 1.19 1.19 299,013
Aug 14, 2026 1.26 1.26 1.19 1.23 1.23 744,545
Aug 13, 2026 1.26 1.30 1.21 1.24 1.24 1,292,910
Aug 12, 2026 1.24 1.25 1.19 1.19 1.19 774,554
Aug 11, 2026 1.24 1.25 1.21 1.23 1.23 364,060
Aug 10, 2026 1.25 1.28 1.23 1.23 1.23 351,020
Aug 7, 2026 1.27 1.28 1.24 1.26 1.26 459,025
Aug 6, 2026 1.26 1.27 1.23 1.27 1.27 974,681
Aug 5, 2026 1.25 1.28 1.21 1.26 1.26 574,907
Aug 4, 2026 1.15 1.25 1.15 1.23 1.23 752,105
Aug 3, 2026 1.19 1.22 1.12 1.15 1.15 1,373,121
Jul 31, 2026 1.20 1.21 1.17 1.17 1.17 824,576
Jul 30, 2026 1.20 1.22 1.18 1.20 1.20 487,670
Jul 29, 2026 1.20 1.21 1.16 1.19 1.19 1,055,670
Jul 28, 2026 1.18 1.28 1.15 1.20 1.20 1,602,358
Jul 27, 2026 1.20 1.23 1.16 1.18 1.18 1,346,955
Jul 24, 2026 1.14 1.23 1.08 1.19 1.19 11,767,489
Jul 23, 2026 1.28 1.28 1.10 1.16 1.16 3,732,613
Jul 22, 2026 1.38 1.41 1.25 1.27 1.27 1,990,449
Jul 21, 2026 1.43 1.44 1.37 1.38 1.38 2,181,809
Jul 20, 2026 1.57 1.57 1.41 1.44 1.44 1,718,822
Jul 17, 2026 1.52 1.64 1.50 1.58 1.58 1,249,349
Jul 16, 2026 1.68 1.69 1.51 1.57 1.57 2,627,725
Jul 15, 2026 1.71 1.71 1.63 1.70 1.70 1,425,250
Jul 14, 2026 2.17 2.34 1.67 1.70 1.70 11,306,840
Jul 13, 2026 2.11 2.19 2.07 2.18 2.18 703,993
Jul 10, 2026 2.12 2.16 2.05 2.10 2.10 482,147
Jul 9, 2026 2.19 2.19 2.12 2.12 2.12 369,777
Jul 8, 2026 2.14 2.23 2.12 2.17 2.17 303,938
Jul 7, 2026 2.16 2.19 2.12 2.16 2.16 879,844
Jul 6, 2026 2.17 2.21 2.15 2.19 2.19 372,735
Jul 2, 2026 2.23 2.28 2.15 2.20 2.20 629,524
Jul 1, 2026 2.21 2.27 2.21 2.22 2.22 397,551
Jun 30, 2026 2.26 2.29 2.20 2.21 2.21 435,192
Jun 29, 2026 2.26 2.33 2.25 2.26 2.26 518,253
Jun 26, 2026 2.03 2.33 2.01 2.26 2.26 2,222,022
Jun 25, 2026 2.12 2.13 2.02 2.02 2.02 1,146,404
Jun 24, 2026 2.15 2.23 2.10 2.10 2.10 893,780
Jun 23, 2026 2.16 2.23 2.15 2.15 2.15 609,657
Jun 22, 2026 2.27 2.36 2.16 2.21 2.21 2,271,190
Jun 18, 2026 2.51 2.51 2.15 2.28 2.28 7,195,319
Jun 17, 2026 2.87 3.05 1.95 2.11 2.11 11,185,567
Jun 16, 2026 2.94 2.98 2.75 2.77 2.77 1,432,159
Jun 15, 2026 2.93 2.97 2.85 2.91 2.91 938,025
Jun 12, 2026 2.72 2.85 2.70 2.85 2.85 623,936
Jun 11, 2026 2.55 2.76 2.48 2.70 2.70 1,156,442
Jun 10, 2026 2.62 2.63 2.50 2.54 2.54 762,512
Jun 9, 2026 2.78 2.81 2.52 2.57 2.57 1,129,218
Jun 8, 2026 2.84 2.87 2.73 2.74 2.74 649,253
Jun 5, 2026 3.00 3.00 2.76 2.82 2.82 756,307
Jun 4, 2026 2.79 3.07 2.78 2.98 2.98 1,026,065
Jun 3, 2026 2.86 2.87 2.77 2.80 2.80 775,516
Jun 2, 2026 2.81 2.87 2.76 2.83 2.83 606,437
Jun 1, 2026 2.83 2.89 2.79 2.83 2.83 649,029
May 29, 2026 2.92 2.92 2.75 2.83 2.83 1,340,207
May 28, 2026 2.93 3.00 2.90 2.90 2.90 791,950
May 27, 2026 2.86 3.08 2.81 2.93 2.93 1,774,387
May 26, 2026 2.80 2.94 2.76 2.86 2.86 1,516,806
May 22, 2026 2.71 2.85 2.69 2.76 2.76 545,468
May 21, 2026 2.63 2.71 2.56 2.69 2.69 433,214
May 20, 2026 2.59 2.65 2.55 2.63 2.63 320,203
May 19, 2026 2.52 2.62 2.50 2.59 2.59 323,160
May 18, 2026 2.77 2.79 2.57 2.58 2.58 917,938
May 15, 2026 2.71 2.88 2.69 2.79 2.79 938,966
May 14, 2026 2.44 2.76 2.37 2.76 2.76 1,606,705
May 13, 2026 2.56 2.56 2.42 2.44 2.44 675,027
May 12, 2026 2.51 2.56 2.48 2.54 2.54 350,939
May 11, 2026 2.62 2.67 2.54 2.55 2.55 431,855
May 8, 2026 2.52 2.58 2.49 2.56 2.56 355,975
May 7, 2026 2.54 2.62 2.50 2.51 2.51 566,249
May 6, 2026 2.47 2.56 2.44 2.53 2.53 620,277
May 5, 2026 2.51 2.58 2.41 2.42 2.42 506,928
May 4, 2026 2.50 2.61 2.46 2.50 2.50 462,338
May 1, 2026 2.54 2.63 2.48 2.48 2.48 494,431
Apr 30, 2026 2.50 2.58 2.50 2.51 2.51 363,858
Apr 29, 2026 2.65 2.66 2.47 2.53 2.53 828,454
Apr 28, 2026 2.68 2.73 2.67 2.67 2.67 219,094
Apr 27, 2026 2.74 2.75 2.67 2.67 2.67 322,735
Apr 24, 2026 2.82 2.82 2.74 2.74 2.74 346,529
Apr 23, 2026 2.86 2.91 2.79 2.80 2.80 297,031
Apr 22, 2026 2.84 2.92 2.84 2.86 2.86 319,737
Apr 21, 2026 2.82 2.82 2.74 2.80 2.80 266,215
Apr 20, 2026 2.73 2.86 2.71 2.84 2.84 395,812
Apr 17, 2026 2.71 2.78 2.65 2.75 2.75 381,209
Apr 16, 2026 2.64 2.71 2.62 2.68 2.68 552,122
Apr 15, 2026 2.78 2.80 2.63 2.64 2.64 696,141
Apr 14, 2026 2.84 2.88 2.76 2.78 2.78 603,729
Apr 13, 2026 2.67 2.86 2.67 2.78 2.78 614,602
Apr 10, 2026 2.80 2.80 2.62 2.67 2.67 786,982
Apr 9, 2026 2.72 2.80 2.67 2.78 2.78 450,193
Apr 8, 2026 2.70 2.75 2.60 2.72 2.72 426,784
Apr 7, 2026 2.59 2.69 2.48 2.67 2.67 693,208
Apr 6, 2026 2.44 2.61 2.44 2.61 2.61 478,894
Apr 2, 2026 2.41 2.45 2.38 2.43 2.43 214,374
Apr 1, 2026 2.35 2.48 2.34 2.45 2.45 402,251
Mar 31, 2026 2.29 2.35 2.21 2.34 2.34 485,409
Mar 30, 2026 2.39 2.43 2.24 2.24 2.24 314,027
Mar 27, 2026 2.30 2.44 2.28 2.33 2.33 498,713
Mar 26, 2026 2.39 2.48 2.34 2.37 2.37 482,614
Mar 25, 2026 2.39 2.46 2.37 2.41 2.41 189,257
Mar 24, 2026 2.29 2.47 2.29 2.37 2.37 394,992
Mar 23, 2026 2.37 2.41 2.33 2.35 2.35 176,547
Mar 20, 2026 2.47 2.47 2.35 2.37 2.37 235,757
Mar 19, 2026 2.45 2.48 2.38 2.47 2.47 201,826
Mar 18, 2026 2.58 2.58 2.40 2.46 2.46 351,569
Mar 17, 2026 2.58 2.70 2.57 2.58 2.58 389,628
Mar 16, 2026 2.57 2.62 2.55 2.59 2.59 214,874
Mar 13, 2026 2.58 2.60 2.51 2.58 2.58 200,360
Mar 12, 2026 2.56 2.64 2.50 2.59 2.59 344,900
Mar 11, 2026 2.43 2.60 2.40 2.59 2.59 620,108
Mar 10, 2026 2.31 2.46 2.31 2.45 2.45 540,284
Mar 9, 2026 2.27 2.35 2.22 2.32 2.32 377,519
Mar 6, 2026 2.27 2.31 2.25 2.30 2.30 142,308
Mar 5, 2026 2.26 2.30 2.22 2.29 2.29 178,365
Mar 4, 2026 2.21 2.31 2.20 2.29 2.29 315,136
Mar 3, 2026 2.13 2.21 2.11 2.19 2.19 228,839
Mar 2, 2026 2.12 2.21 2.12 2.19 2.19 195,918
Feb 27, 2026 2.22 2.27 2.15 2.17 2.17 290,164
Feb 26, 2026 2.22 2.25 2.17 2.21 2.21 273,237
Feb 25, 2026 2.22 2.25 2.19 2.22 2.22 236,714
Feb 24, 2026 2.23 2.25 2.15 2.23 2.23 682,853
Feb 23, 2026 2.32 2.33 2.20 2.24 2.24 565,908
Feb 20, 2026 2.38 2.39 2.28 2.30 2.30 159,081
Feb 19, 2026 2.33 2.41 2.32 2.40 2.40 172,787
Feb 18, 2026 2.35 2.40 2.31 2.33 2.33 266,054
Feb 17, 2026 2.39 2.40 2.30 2.35 2.35 283,174
Feb 13, 2026 2.38 2.44 2.38 2.39 2.39 136,759
Feb 12, 2026 2.37 2.41 2.31 2.38 2.38 104,212
Feb 11, 2026 2.37 2.43 2.32 2.37 2.37 138,164
Feb 10, 2026 2.40 2.40 2.35 2.36 2.36 173,628
Feb 9, 2026 2.40 2.40 2.27 2.36 2.36 349,226
Feb 6, 2026 2.31 2.43 2.31 2.42 2.42 1,027,764
Feb 5, 2026 2.25 2.49 2.25 2.30 2.30 748,657
Feb 4, 2026 2.26 2.32 2.19 2.29 2.29 937,763
Feb 3, 2026 2.21 2.29 2.10 2.14 2.14 440,521
Feb 2, 2026 2.15 2.27 2.14 2.23 2.23 277,128
Jan 30, 2026 2.24 2.25 2.18 2.19 2.19 244,496
Jan 29, 2026 2.23 2.30 2.22 2.25 2.25 168,873
Jan 28, 2026 2.36 2.37 2.22 2.23 2.23 369,419
Jan 27, 2026 2.45 2.45 2.35 2.37 2.37 244,759
Jan 26, 2026 2.43 2.46 2.37 2.45 2.45 181,741
Jan 23, 2026 2.44 2.46 2.42 2.44 2.44 151,710
Jan 22, 2026 2.34 2.46 2.32 2.45 2.45 299,606
Jan 21, 2026 2.38 2.40 2.32 2.36 2.36 160,224
Jan 20, 2026 2.40 2.40 2.31 2.38 2.38 276,760
Jan 16, 2026 2.40 2.42 2.34 2.41 2.41 266,138
Jan 15, 2026 2.50 2.51 2.39 2.40 2.40 222,282
Jan 14, 2026 2.45 2.52 2.41 2.51 2.51 215,618
Jan 13, 2026 2.51 2.52 2.44 2.45 2.45 168,061
Jan 12, 2026 2.53 2.54 2.48 2.51 2.51 167,825
Jan 9, 2026 2.57 2.57 2.52 2.55 2.55 150,689
Jan 8, 2026 2.59 2.60 2.51 2.57 2.57 284,645
Jan 7, 2026 2.51 2.65 2.49 2.60 2.60 322,197
Jan 6, 2026 2.44 2.52 2.42 2.51 2.51 283,155
Jan 5, 2026 2.38 2.47 2.38 2.43 2.43 304,552
Jan 2, 2026 2.32 2.37 2.30 2.35 2.35 247,408
Dec 31, 2025 2.27 2.33 2.27 2.33 2.33 218,071
Dec 30, 2025 2.29 2.30 2.27 2.27 2.27 195,538
Dec 29, 2025 2.31 2.32 2.27 2.30 2.30 163,617
Dec 26, 2025 2.33 2.37 2.27 2.32 2.32 280,387
Dec 24, 2025 2.32 2.36 2.31 2.34 2.34 89,843
Dec 23, 2025 2.36 2.42 2.31 2.33 2.33 245,253
Dec 22, 2025 2.32 2.37 2.29 2.37 2.37 260,266
Dec 19, 2025 2.35 2.42 2.28 2.32 2.32 465,242
Dec 18, 2025 2.33 2.33 2.28 2.29 2.29 290,860
Dec 17, 2025 2.29 2.38 2.29 2.31 2.31 308,549
Dec 16, 2025 2.29 2.31 2.25 2.27 2.27 202,614
Dec 15, 2025 2.33 2.35 2.29 2.29 2.29 208,150
Dec 12, 2025 2.36 2.36 2.30 2.32 2.32 287,791
Dec 11, 2025 2.33 2.36 2.31 2.35 2.35 186,053
Dec 10, 2025 2.34 2.39 2.31 2.33 2.33 335,973
Dec 9, 2025 2.31 2.35 2.25 2.33 2.33 349,458
Dec 8, 2025 2.29 2.36 2.27 2.31 2.31 323,470
Dec 5, 2025 2.29 2.31 2.25 2.26 2.26 161,019
Dec 4, 2025 2.27 2.33 2.24 2.28 2.28 241,722
Dec 3, 2025 2.21 2.29 2.18 2.28 2.28 364,377
Dec 2, 2025 2.28 2.29 2.20 2.20 2.20 505,006
Dec 1, 2025 2.33 2.38 2.26 2.27 2.27 367,562
Nov 28, 2025 2.35 2.42 2.33 2.40 2.40 136,577
Nov 26, 2025 2.35 2.38 2.28 2.33 2.33 363,195
Nov 25, 2025 2.37 2.37 2.30 2.34 2.34 284,206
Nov 24, 2025 2.34 2.40 2.33 2.38 2.38 627,019
Nov 21, 2025 2.22 2.33 2.21 2.31 2.31 171,815
Nov 20, 2025 2.40 2.42 2.23 2.26 2.26 435,118
Nov 19, 2025 2.47 2.47 2.33 2.38 2.38 512,698
Nov 18, 2025 2.40 2.49 2.37 2.47 2.47 325,366
Nov 17, 2025 2.41 2.57 2.41 2.43 2.43 635,133
Nov 14, 2025 2.39 2.48 2.33 2.41 2.41 251,250
Nov 13, 2025 2.66 2.72 2.43 2.44 2.44 881,763
Nov 12, 2025 2.63 2.75 2.61 2.66 2.66 752,585
Nov 11, 2025 2.50 2.65 2.50 2.62 2.62 675,270
Nov 10, 2025 2.45 2.57 2.45 2.50 2.50 481,910
Nov 7, 2025 2.38 2.46 2.35 2.46 2.46 514,784
Nov 6, 2025 2.43 2.47 2.38 2.39 2.39 603,829
Nov 5, 2025 2.35 2.48 2.35 2.43 2.43 596,286
Nov 4, 2025 2.35 2.47 2.33 2.35 2.35 706,066
Nov 3, 2025 2.44 2.46 2.32 2.38 2.38 447,720
Oct 31, 2025 2.35 2.48 2.33 2.43 2.43 493,271
Oct 30, 2025 2.33 2.44 2.31 2.36 2.36 332,813
Oct 29, 2025 2.37 2.40 2.30 2.33 2.33 433,938
Oct 28, 2025 2.28 2.42 2.27 2.38 2.38 585,780
Oct 27, 2025 2.22 2.30 2.21 2.29 2.29 296,186
Oct 24, 2025 2.20 2.25 2.19 2.21 2.21 451,821
Oct 23, 2025 2.24 2.28 2.16 2.20 2.20 667,257
Oct 22, 2025 2.30 2.32 2.24 2.25 2.25 1,165,741
Oct 21, 2025 2.31 2.50 2.30 2.37 2.37 12,750,029
Oct 20, 2025 2.22 2.32 2.22 2.29 2.29 376,862
Oct 17, 2025 2.31 2.32 2.21 2.21 2.21 619,037
Oct 16, 2025 2.50 2.52 2.34 2.35 2.35 485,800
Oct 15, 2025 2.40 2.49 2.36 2.49 2.49 593,716
Oct 14, 2025 2.24 2.38 2.24 2.36 2.36 449,224
Oct 13, 2025 2.35 2.41 2.24 2.29 2.29 553,849
Oct 10, 2025 2.38 2.41 2.25 2.25 2.25 822,415
Oct 9, 2025 2.35 2.42 2.32 2.36 2.36 591,433
Oct 8, 2025 2.18 2.35 2.18 2.28 2.28 796,193
Oct 7, 2025 2.08 2.19 2.06 2.16 2.16 748,336
Oct 6, 2025 2.04 2.13 2.02 2.09 2.09 384,358
Oct 3, 2025 2.01 2.09 1.99 2.05 2.05 379,982
Oct 2, 2025 1.99 2.04 1.94 2.03 2.03 204,086
Oct 1, 2025 1.89 1.98 1.89 1.96 1.96 391,031
Sep 30, 2025 1.91 1.91 1.84 1.88 1.88 385,870
Sep 29, 2025 1.89 1.93 1.88 1.90 1.90 158,728
Sep 26, 2025 1.93 1.96 1.87 1.89 1.89 397,502
Sep 25, 2025 1.98 1.98 1.91 1.94 1.94 249,715
Sep 24, 2025 2.02 2.04 1.97 1.97 1.97 256,042
Sep 23, 2025 2.00 2.05 1.98 2.01 2.01 193,102

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Spero Therapeutics, Inc. Common Stock Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at SPRO, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation